Market Cap 3.60B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 88.90
Forward PE N/A
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 284,800
Avg Vol 194,220
Day's Range N/A - N/A
Shares Out 19.68M
Stochastic %K 45%
Beta 0.99
Analysts Strong Sell
Price Target $232.00

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pn...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:27 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $180.59, significantly below its 60D high of $212.49, indicating potential for a rebound. The RSI at 27.92 suggests oversold conditions, which historically precede upward price movements. Directional Bias: The bearish trend is evident with the MA30 at $197.06 and MA50 at $191.69, but the low RSI indicates a possible reversal. The price is near the 60D low of $163.45, providing a solid base for a potential bounce. Trade Plan: - Suggested Entry: $180.59 - Stop Loss: $175.00 (to limit downside risk) - Take Profit Targets: 1. $190.00 (5% ROI) 2. $200.00 (10.76% ROI) 3. $211.00 (16.83% ROI) This plan offers a favorable risk-reward ratio with a potential ROI exceeding 17% at the third target. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
BinaryLogic
BinaryLogic Dec. 11 at 2:22 AM
$OBIO [Again] Partnerships with $MDT and $LGND, 137 global patents, breakthrough device designation, Cash runway to 1H-2027 with $95M Cash/ST against $61M Total Liabilities. Avg PT: $13.8 and currently trading at $4.75. TD Cowen just provided its forecast (PT) at $15. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-announces-avim-therapy-and-virtue-sab-program-7359wz18v149.html
0 · Reply
IN0V8
IN0V8 Dec. 10 at 4:29 PM
$LGND Buy Stifel raises target price to $230 from $220
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 2:26 PM
RBC Capital has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Outperform with a target price of 234 → 235.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 1:05 PM
Stifel has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Buy with a price target of 230.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:30 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $185.83, significantly below its 60-day high of $212.49, indicating potential for a rebound. The RSI at 26.18 suggests the stock is oversold, providing a bullish signal for a reversal. Directional Bias: Given the RSI's oversold condition and the price being below both the 30-day MA (197.36) and 50-day MA (191.52), there is a strong possibility of upward movement towards these moving averages. The 60-day low of $163.10 provides a solid support level. Trade Plan: - Suggested Entry: $186.00 - Stop Loss: $179.00 (approx. 3.2% risk) - Take Profit Targets: 1. $195.00 (5% gain) 2. $202.00 (8.6% gain) 3. $217.00 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target, capitalizing on the oversold condition and the upward potential towards the moving averages. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 7:37 PM
Citigroup has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Buy with a target price of 270.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 9 at 5:54 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:19 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $187.48, below both the 30-day moving average (MA30) of $197.59 and the 50-day moving average (MA50) of $191.32. The RSI at 36.53 indicates that the stock is nearing oversold territory, suggesting potential for a rebound. Directional Bias: Given the current price is closer to the 60D low of $161.82 than the high of $212.49, there is a bearish sentiment. However, the low RSI indicates a possible reversal opportunity. Trade Plan: - Suggested Entry: $187.50 - Stop Loss: $179.57 (1 ATR below entry) - Take Profit Targets: 1. $197.50 (Target 1: 5.4% ROI) 2. $205.00 (Target 2: 9.3% ROI) 3. $219.00 (Target 3: 16.8% ROI) This plan offers a solid risk-reward ratio with a potential 17% ROI on the third target. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:18 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $188.5, below its 30-day moving average (MA30) of $197.58 and 50-day moving average (MA50) of $190.61, indicating a bearish trend. The RSI at 36.16 suggests that the stock is nearing oversold territory, which could signal a potential reversal. Directional Bias: Given the current RSI and the position relative to MAs, there is a likelihood of a short-term bounce. The 60-day high of $212.49 provides a potential upside target, while the low of $161.82 offers a clear downside risk. Trade Plan: - Suggested Entry: $188.5 - Stop Loss: $180.0 (4.3% risk) - Take Profit Targets: 1. $198.0 (5% gain) 2. $205.0 (8.7% gain) 3. $220.0 (16.7% gain) This plan provides a risk-reward ratio favorable for a potential 17% ROI on the third target. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
Latest News on LGND
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Dec 9, 2025, 7:00 AM EST - 4 days ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance


Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 6 weeks ago

Ligand to Participate in November Investor Conferences


Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 2 months ago

Ligand to Host Investor Day on December 9, 2025


Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 4 months ago

Ligand to Participate in September Investor Conferences


Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 4 months ago

Ligand Announces Closing of Convertible Senior Notes Offering


Ligand (LGND) Q2 Revenue Jumps 15%

Aug 7, 2025, 9:10 AM EDT - 4 months ago

Ligand (LGND) Q2 Revenue Jumps 15%


Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 5 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™


Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Jun 24, 2025, 2:47 PM EDT - 6 months ago

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward


Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 6 months ago

Ligand Announces 2025 Investor Day in New York City


Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 7 months ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025


Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 7 months ago

Ligand Reports First Quarter 2025 Financial Results


Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 8 months ago

Ligand to Participate in May Investor Conferences


Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 10 months ago

Ligand to Participate in March Investor Conferences


Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 10 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results


Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 11 months ago

Looking Back On Ligand Pharmaceuticals


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:27 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $180.59, significantly below its 60D high of $212.49, indicating potential for a rebound. The RSI at 27.92 suggests oversold conditions, which historically precede upward price movements. Directional Bias: The bearish trend is evident with the MA30 at $197.06 and MA50 at $191.69, but the low RSI indicates a possible reversal. The price is near the 60D low of $163.45, providing a solid base for a potential bounce. Trade Plan: - Suggested Entry: $180.59 - Stop Loss: $175.00 (to limit downside risk) - Take Profit Targets: 1. $190.00 (5% ROI) 2. $200.00 (10.76% ROI) 3. $211.00 (16.83% ROI) This plan offers a favorable risk-reward ratio with a potential ROI exceeding 17% at the third target. Monitor market conditions closely for any changes. https://privateprofiteers.com
0 · Reply
BinaryLogic
BinaryLogic Dec. 11 at 2:22 AM
$OBIO [Again] Partnerships with $MDT and $LGND, 137 global patents, breakthrough device designation, Cash runway to 1H-2027 with $95M Cash/ST against $61M Total Liabilities. Avg PT: $13.8 and currently trading at $4.75. TD Cowen just provided its forecast (PT) at $15. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-announces-avim-therapy-and-virtue-sab-program-7359wz18v149.html
0 · Reply
IN0V8
IN0V8 Dec. 10 at 4:29 PM
$LGND Buy Stifel raises target price to $230 from $220
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 2:26 PM
RBC Capital has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Outperform with a target price of 234 → 235.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 1:05 PM
Stifel has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Buy with a price target of 230.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:30 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $185.83, significantly below its 60-day high of $212.49, indicating potential for a rebound. The RSI at 26.18 suggests the stock is oversold, providing a bullish signal for a reversal. Directional Bias: Given the RSI's oversold condition and the price being below both the 30-day MA (197.36) and 50-day MA (191.52), there is a strong possibility of upward movement towards these moving averages. The 60-day low of $163.10 provides a solid support level. Trade Plan: - Suggested Entry: $186.00 - Stop Loss: $179.00 (approx. 3.2% risk) - Take Profit Targets: 1. $195.00 (5% gain) 2. $202.00 (8.6% gain) 3. $217.00 (16.7% gain) This trade plan offers a potential ROI of over 17% on the third target, capitalizing on the oversold condition and the upward potential towards the moving averages. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 7:37 PM
Citigroup has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Buy with a target price of 270.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 9 at 5:54 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:19 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $187.48, below both the 30-day moving average (MA30) of $197.59 and the 50-day moving average (MA50) of $191.32. The RSI at 36.53 indicates that the stock is nearing oversold territory, suggesting potential for a rebound. Directional Bias: Given the current price is closer to the 60D low of $161.82 than the high of $212.49, there is a bearish sentiment. However, the low RSI indicates a possible reversal opportunity. Trade Plan: - Suggested Entry: $187.50 - Stop Loss: $179.57 (1 ATR below entry) - Take Profit Targets: 1. $197.50 (Target 1: 5.4% ROI) 2. $205.00 (Target 2: 9.3% ROI) 3. $219.00 (Target 3: 16.8% ROI) This plan offers a solid risk-reward ratio with a potential 17% ROI on the third target. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:18 AM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $188.5, below its 30-day moving average (MA30) of $197.58 and 50-day moving average (MA50) of $190.61, indicating a bearish trend. The RSI at 36.16 suggests that the stock is nearing oversold territory, which could signal a potential reversal. Directional Bias: Given the current RSI and the position relative to MAs, there is a likelihood of a short-term bounce. The 60-day high of $212.49 provides a potential upside target, while the low of $161.82 offers a clear downside risk. Trade Plan: - Suggested Entry: $188.5 - Stop Loss: $180.0 (4.3% risk) - Take Profit Targets: 1. $198.0 (5% gain) 2. $205.0 (8.7% gain) 3. $220.0 (16.7% gain) This plan provides a risk-reward ratio favorable for a potential 17% ROI on the third target. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:53 PM
Actionable Trade Alert for $LGND: Market Context: $LGND is currently trading at $188.5, below its 30-day moving average (MA30) of $197.58 and 50-day moving average (MA50) of $190.61, indicating a bearish trend. The RSI at 36.16 suggests that the stock is nearing oversold territory, which could signal a potential reversal. Directional Bias: Given the current RSI and the position relative to MAs, there is a likelihood of a short-term bounce. The 60-day high of $212.49 provides a potential upside target, while the low of $161.82 offers a clear downside risk. Trade Plan: - Suggested Entry: $188.5 - Stop Loss: $180.0 (4.3% risk) - Take Profit Targets: 1. $198.0 (5% gain) 2. $205.0 (8.7% gain) 3. $220.0 (16.7% gain) This plan provides a risk-reward ratio favorable for a potential 17% ROI on the third target. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
tyogs
tyogs Dec. 1 at 6:55 PM
$LGND possible bounce off the high 180s then retest 200 bucks. Could shoot higher from there or reject until next earnings.
0 · Reply
MichaelKTrades
MichaelKTrades Nov. 26 at 9:49 PM
$LGND 4 week flat base
0 · Reply
Doozio
Doozio Nov. 25 at 5:56 PM
They did say it wud be $LGND ary during 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Nov. 25 at 12:25 PM
Roth🏁 $PTHS Buy/$57 $VRCA $LGND $GSK $TEVA Roth said—We initiate coverage of PTHS with a Buy rating and a 12-month price target of $57, based on a DCF analysis (25% discount rate and 5x multiple of our projected $104M 2033 operating income). We project growing revenue from Zelsuvmi (launched 3Q25) and Xepi (late 2026 launch) in molluscum contagiosum and impetigo, respectively. PTHS has pro forma cash of $28M (3Q25 cash of $14.2M, plus $18M convertible debt raised in 4Q25, minus $4.2M paid upfront for Xepi in 4Q25), which funds operations to cash flow breakeven by YE26, per our projections, and $18M in debt.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 23 at 10:47 PM
Attached is a table that documents certain valuation related data points of a pool of newer commercial-stage non-oncology focused bios (those with 1st approvals since 1/1/2020). The table includes a handful of older such bios. We're interested in the 5 on the bottom. Genuine responses would be appreciated on; $BCRX For those investors that believe some commercial-stage bios trade in cycles, is BCRX near a bottom? $TVTX has more than doubled the last 6 month yet still trades at meaningfully lower multiples than peers. $LGND multiples are "off-the-charts" but investors often cite low forecasts from future royalties including TVTX $FOLD Are there any updates on the generic? $APLS ? This is not investment advice. We're genuinely curious as our club has a major re-balance at year end (we plan for now).
3 · Reply
Elevator_up
Elevator_up Nov. 19 at 11:49 AM
$VKTX $LGND Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year • good article- regarding Ligand. • would encourage those interested to track the connection with VK2809. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/?gaa_at=la&gaa_n=AWEtsqdclWpJXKi3Rb6hVu1Hg7SyaRHwRLSoL7a2f4YUo8qUs-KMkigD0kv9Cnwc5d4%3D&gaa_ts=691daee8&utm_source=newsshowcase&utm_medium=discover&utm_campaign=CCwqGQgwKhAIACoHCAowzpuGCzCQ9YMDMKqx3wQwtrGZBQ&utm_content=bullets&gaa_sig=kvLVeDBy9H_SoRl__TUm2l7ssDvfiFuHQaNHmshLvGRrvynX_NCxKyaZN59BE4q1lkJSqOLWPWX4fNgJNhmHsg%3D%3D
2 · Reply
SuperGreenToday
SuperGreenToday Nov. 14 at 5:36 PM
$LGND Share Price: $204.93 Contract Selected: May 15, 2026 $200 Calls Buy Zone: $18.27 – $22.57 Target Zone: $33.62 – $41.09 Potential Upside: 74% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 3:33 PM
Results List 11/2025 13;days to go. $LC $LGND $LLYX $LITE $LLY
0 · Reply
Doozio
Doozio Nov. 11 at 2:38 AM
With moar of that volume how $LGND $ARRY can it get during 🐒🍌🧠⏰♾️?
0 · Reply
ZacksSCR
ZacksSCR Nov. 10 at 8:07 PM
$LGND: Target Up On Improved Growth Outlook https://buff.ly/3KAJ8jQ
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 3:57 PM
RBC Capital has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Outperform with a price target of 234.
0 · Reply